Sanofi and GlaxoSmithKline said Oct. 28 that they will provide 200 million doses of their COVID-19 vaccine to the World Health Organizations Covax effort if the vaccine gets regulatory approval..
The initiative is focused on focusing on vaccination for the most high-risk people in every country, and the WHO has stated it prepares for all nations to receive adequate dosages of a vaccine to immunize 20 percent of their population before any nation receives more dosages, CNBC reported..
Maia Anderson –
Wednesday, October 28th, 2020
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
If information is positive, Sanofi and GlaxoSmithKline stated they anticipate outcomes from their phase 2 trial of their experimental COVID-19 vaccine by early December and will launch a stage 3 trial. The drugmakers said they plan to seek regulatory approval in the first half of 2021 if data from all trials is favorable..
Read Sanofis complete news release here.
More short articles on pharmacy: FDA is letting COVID-19 vaccine makers skip inspection prior to emergency situation authorizationVertex prompted to address deadly inequality in access to its cystic fibrosis drugCVS to add fast COVID-19 testing at 1,000 drug stores.
The Covax initiative looks for to make sure COVID-19 vaccines are dispersed equitably all over the world and intends to provide 2 billion doses of the vaccine by the end of 2021, according to CNBC. More than 180 nations have actually joined the effort, however the U.S. has not..